{
  "pmcid": "8625160",
  "sha256": "aad134637a0d5b66b2d8f7be86143f0202775a263455e8a94489c1ae3cc68e3d",
  "timestamp_utc": "2025-11-09T22:58:57.393385+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.80913139087411,
    "reading_ease": 25.64859538207807,
    "word_count": 214
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Stem Cell Therapy for Myocardial Regeneration"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was performed using a computer-generated sequence"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants with ischemic cardiac injury and NYHA class I-III symptoms were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received 150 million autologous BM MSCs, 5 million c-kit+ CPCs, or both via transendocardial injection. The control group received PlasmaLyte A."
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the impact of stem cell therapy on cardiac function."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in left ventricular ejection fraction (LVEF) over six months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding included outcome assessors and patients."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 144 participants were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "125 completing the study"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "LVEF changes were not significantly different between groups. However, major adverse cardiac events decreased significantly in the CPC group (p = 0.043)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No severe adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02501811"
      },
      "Funding": {
        "score": 1,
        "evidence": "Supported by the National Institutes of Health."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}